Arcutis Announces Positive Topline Data from Phase 2b Study of ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Scalp and Body Psoriasis

NEXT STORY
Adaptive Biotechnologies and Collaborators to Present Data from More Than 35 Abstracts at ASH 2020 Highlighting Clinical Relevance of MRD Testing with the clonoSEQ® Assay in Blood Cancer Patients
PREV STORY
Mereo BioPharma Appoints Suba Krishnan, M.D. as Senior Vice President of Clinical Development
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Tiziana Responds to UK Call for Development of Innovative ‘Take Home’ Treatments for COVID-19 Disease

author_avatar
NASDAQ Market News

NOVAVAX, INC. (NASDAQ: NVAX) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Novavax, Inc.

author_avatar
NASDAQ Market News

New Results From COSMIC-HF Presented at AHA 2019 Show Treatment of Heart Failure Patients With Omecamtiv Mecarbil Was Associated With Neutral or Improved Measures of Diastolic Function

author_avatar
NASDAQ Market News